Liu Yayue, Zhu Kangwei, Tian Xindi, Chen Ping, Xiong Qingqing, Li Guangtao, Ma Xiaochen, Han Ruyu, Sun Liyu, Shen Yijian, Zhu Fengyi, Wang Yimeng, Chen Lu, Song Tianqiang
Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
National Clinical Research Center for Cancer, Tianjin 300060, China.
Cancers (Basel). 2025 Jun 9;17(12):1919. doi: 10.3390/cancers17121919.
Gallbladder cancer (GBC) is a rare but aggressive malignancy. Prognostic tools are essential for optimizing postoperative treatment strategies. We aim to develop and validate a prognostic nomogram to estimate 1-, 3-, and 5-year overall survival (OS) in GBC patients and explore the role of adjuvant chemotherapy across different subgroups.
A total of 1848 postoperative GBC patients from the SEER database (2000-2020 17 regions) were analyzed, with an additional external validation cohort of 108 patients from China (2010-2020). Prognostic factors were identified using LASSO regression and multivariable Cox analysis. A nomogram was constructed and validated using the concordance index (C-index), time-dependent ROC curves, calibration curves, and decision curve analysis (DCA). Subgroup analyses were performed to evaluate the impact of adjuvant chemotherapy.
The nomogram demonstrated strong predictive performance, with C-indices of 0.767 (training), 0.798 (internal validation), and 0.750 (external validation). Time-dependent ROC curves in the training cohort showed AUCs of 0.777, 0.769, and 0.800 for 1-, 3-, and 5-year OS, respectively. In the internal validation cohort, the corresponding AUCs were 0.763, 0.743, and 0.803. External validation using the independent Chinese cohort of 108 patients showed consistent results, with AUCs of 0.771, 0.835, and 0.810 for 1-, 3-, and 5-year OS. Subgroup analysis revealed that adjuvant chemotherapy significantly improved survival in patients with TNM stage >IIB. In contrast, patients with early-stage disease (TNM ≤ IIB) showed no significant survival benefit from chemotherapy.
This study developed a validated prognostic nomogram for postoperative GBC patients, demonstrating strong discrimination and calibration. Subgroup analysis suggests that adjuvant chemotherapy benefits select high-risk patients, aiding personalized decision-making in clinical practice.
胆囊癌(GBC)是一种罕见但侵袭性强的恶性肿瘤。预后工具对于优化术后治疗策略至关重要。我们旨在开发并验证一种预后列线图,以估计GBC患者的1年、3年和5年总生存率(OS),并探讨辅助化疗在不同亚组中的作用。
分析了来自SEER数据库(2000 - 2020年,17个地区)的1848例GBC术后患者,并纳入了来自中国的108例患者组成的外部验证队列(2010 - 2020年)。使用LASSO回归和多变量Cox分析确定预后因素。使用一致性指数(C指数)、时间依赖性ROC曲线、校准曲线和决策曲线分析(DCA)构建并验证列线图。进行亚组分析以评估辅助化疗的影响。
列线图显示出强大的预测性能,训练集的C指数为0.767,内部验证集为0.798,外部验证集为0.750。训练队列中的时间依赖性ROC曲线显示,1年、3年和5年OS的AUC分别为0.777、0.769和0.800。在内部验证队列中,相应的AUC分别为0.763、0.743和0.803。使用108例中国独立队列进行的外部验证显示了一致的结果,1年、3年和5年OS的AUC分别为0.771、0.835和0.810。亚组分析显示,辅助化疗显著改善了TNM分期>IIB患者的生存率。相比之下,早期疾病(TNM≤IIB)患者未显示出化疗对生存的显著益处。
本研究为GBC术后患者开发了一种经过验证的预后列线图,具有强大的区分度和校准度。亚组分析表明,辅助化疗对特定高危患者有益,有助于临床实践中的个性化决策。